CircRAD23B-208aa Promotes Gastric Cancer Progression by Activating the Unfolded Protein Response through PDIA5 SUMOylation.

Yuli Chen, Jiahao Guo, Ziwei Li, Shaokun Yu, Xiao Ke, Qinnan Chen, Hao Wu, Ming Sun, Fengqi Nie, Xianghua Liu

Abstract read

In one paragraph

Article in Research (Washington, D.C.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuli ChenDepartment of Oncology, Suzhou Cancer Center Core Laboratory, Oncology Laboratory of Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu Province, China.

Jiahao GuoDepartment of Oncology, Suzhou Cancer Center Core Laboratory, Oncology Laboratory of Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu Province, China.

Ziwei LiDepartment of Oncology, Suzhou Cancer Center Core Laboratory, Oncology Laboratory of Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu Province, China.

Shaokun YuDepartment of Oncology, Suzhou Cancer Center Core Laboratory, Oncology Laboratory of Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu Province, China.

Xiao KeDepartment of Oncology, Suzhou Cancer Center Core Laboratory, Oncology Laboratory of Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu Province, China.

Qinnan ChenDepartment of Oncology, Suzhou Cancer Center Core Laboratory, Oncology Laboratory of Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu Province, China.

Hao WuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China.

Ming SunDepartment of Oncology, Suzhou Cancer Center Core Laboratory, Oncology Laboratory of Medical Science and Technology Innovation Center, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou, Jiangsu Province, China.ORCID https://orcid.org/0000-0002-1173-2288

Fengqi NieDepartment of Oncology, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu Province, China.

Xianghua LiuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer (GC) remains a lethal malignancy with limited therapeutic options and poor prognosis. In this study, we employed integrated RNA sequencing and ribosome nascent-chain complex sequencing analyses to identify a coding circular RNA (circRNA), circRAD23B, which is markedly up-regulated in GC tissues. Its expression correlates strongly with advanced tumor stage, lymph node metastasis, and reduced overall survival. We further demonstrate that the splicing factor U2AF65 facilitates circRAD23B biogenesis through direct binding to intron 1 of the RAD23B pre-mRNA. Functionally, circRAD23B encodes a novel 208-amino acid protein via an internal ribosome entry site-dependent mechanism. This protein promotes GC proliferation, invasion, and lung metastasis in vivo. Mechanistically, circRAD23B-208aa recruits the E2 ligase UBC9 to catalyze SUMOylation of PDIA5 at lysine 25, thereby attenuating its ubiquitination and enhancing protein stability. Stabilized PDIA5 facilitates ATF6 activation by promoting its proteolytic processing, nuclear translocation, and transcriptional induction of key unfolded protein response (UPR) effectors-TXNRD1 and HERPUD1-thereby alleviating endoplasmic reticulum stress and promoting tumor survival. Our findings reveal circRAD23B-208aa as the first circRNA-encoded activator of the UPR pathway via posttranslational regulation of PDIA5, highlighting the therapeutic potential of targeting the SUMOylation-dependent PDIA5/ATF6 axis in GC.

Identifiers

PMID42491210

DOI10.34133/research.1357

PMCPMC13376384

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.